LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Summary Public Assessment Report

Dalbavancin BE Pharma, (dalbavancin hydrochloride)

SE/H/2642/01/DC

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

Summary Public Assessment Report

Dalbavancin BE Pharma,
dalbavancin, dalbavancin hydrochloride

Powder for concentrate for solution for infusion, 500 mg

This is a summary of the public assessment report (PAR) for Dalbavancin BE Pharma. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Dalbavancin BE Pharma and what is it used for?
The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Xydalba.

The product is used in the treatment of adults and children from birth with infections of the skin or in the layers of flesh below the skin.

How does Dalbavancin BE Pharma work?
Dalbavancin BE Pharma contains the active substance dalbavancin, which is an antibiotic of the glycopeptide group.
Dalbavancin BE Pharma works by killing certain bacteria, which can cause serious infections. It kills these bacteria by interfering with the formation of bacterial cell walls.

How is Dalbavancin BE Pharma used?
The pharmaceutical form is powder for concentrate for solution for infusion.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Dalbavancin BE Pharma have been shown in studies?
No additional studies were needed as the product is a generic medicine that is given by infusion/intravenous injection and contains the same active substance as the reference medicine, Xydalba.

What are the possible side effects from Dalbavancin BE Pharma?
Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.

For the full list of restrictions, see the package leaflet.

Why is Dalbavancin BE Pharma approved?
It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Xydalba, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Dalbavancin BE Pharma?
A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

For more details, please see the full PAR for Dalbavancin BE Pharma on the following website: MRI - Home.

Other information about Dalbavancin BE Pharma, Dalbavancin BE Pharma B.V.
The full PAR for Dalbavancin BE Pharma can be found on the following website: MRI - Home. For more information about treatment with Dalbavancin BE Pharma, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2026-06.